11400 WEST OLYMPIC BLVD., LOS ANGELES, CA
Announces Pricing of $125 Million Underwritten Offering of Common Stock
Immix Biopharma Reports 89% Response Rate in NEXICART-2 Interim Update
Other Events
Announces Pricing of $150 Million Underwritten Offering of Common Stock
95% Complete Response Rate in Interim Update from Relapsed/Refractory AL Amyloidosis Clinical Trial
Annual Report to Security Holders
Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma Enters Amendment No. 1 to At The Market Offering Agreement
Q2
Q1
Amended Annual Report
FY 2025
Q3
Amended Quarterly Report
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Submission Upload
Correspondence